Adjuvant Therapy
Aspirin after adjuvant therapy does not improve colorectal cancer outcomes
Daily aspirin use after standard adjuvant therapy did not improve DFS for patients with colorectal cancer, according to results of a randomized phase 3 study.
Personalized vaccine induces durable immune response in advanced kidney cancer
A personalized vaccine demonstrated the potential to induce long-lasting immune response among people with advanced kidney cancer, according to results of a phase 1 trial.
Intervention improves timely postoperative treatment for people with head and neck cancer
A multilevel, navigation-based intervention led to more timely initiation of postoperative radiation therapy vs. usual care-based patient navigation for people with head and neck squamous cell carcinoma.
Obesity elevates risk for distant recurrence, mortality in early-stage breast cancer
SAN ANTONIO — Elevated BMI increased risk for breast cancer mortality and distant recurrence among women with early-stage disease, according to findings presented at San Antonio Breast Cancer Symposium.
Axillary surgery does not improve outcomes for early-stage breast cancer
SAN ANTONIO — Surgical axillary staging as part of breast-conserving therapy may not be necessary for certain patients with early invasive breast cancer, according to findings presented at San Antonio Breast Cancer Symposium.
Tamoxifen reduces ipsilateral recurrence risk for certain patients with DCIS
SAN ANTONIO — Tamoxifen lowered overall and invasive ipsilateral recurrence among women with “good-risk” ductal carcinoma in situ who opted for breast conservation surgery without radiation.
“Back to the Future”: Developments in Immunotherapy with David Gandara, MD
In this episode, host Shikha Jain, MD, speaks with David Gandara, MD, about how ctDNA and CAR-T cell therapies are transforming precision medicine, the importance of patient reported outcomes and more.
De-escalated adjuvant chemotherapy effective for high-risk retinoblastoma
A shortened adjuvant chemotherapy regimen improved outcomes for infants with unilateral pathologic high-risk retinoblastoma, according to study results.
Strategies needed to reduce death due to low-risk breast cancer
Most breast cancer-specific deaths occur among patients diagnosed with stage I or II disease rather than more advanced disease, according to a SEER database analysis.
Inavolisib regimen extends PFS in PIK3CA-mutated advanced breast cancer
The addition of inavolisib to palbociclib and fulvestrant more than doubled PFS for certain patients with advanced breast cancer, according to results of a randomized phase 3 trial.